Abstracts Archive - Page 2273 of 2425 - ACR Meeting Abstracts

Abstract Number: 2261 • 2012 ACR/ARHP Annual Meeting
Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus
Olívio B. Malheiro¹, Carolina P. Rezende¹, Gilda A. Ferreira² and Fernando M. Reis¹, ¹Obstetrics and Gynecology, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Locomotor System Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem disease, which affects mostly women at reproductive age, and can promote premature ovarian dysfunction related to factors…
Abstract Number: 2222 • 2012 ACR/ARHP Annual Meeting
Spinal Mobility Measures in Normal Individuals – the Mobility Study
Sofia Ramiro¹, Carmen Stolwijk², A.M. Van Tubergen³, Désirée van der Heijde⁴ and Robert Landewé⁵, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: Spinal mobility is one of the core outcomes recommended by the Assessment of Spondyloarthritis international Society (ASAS) for following patients with axial SpA. It…
Abstract Number: 2223 • 2012 ACR/ARHP Annual Meeting
Dysregulation of Chromatin Modification Enzymes in Psoriatic Arthritis
Remy Pollock¹, Fawnda Pellett², Vinod Chandran³ and Dafna D. Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Chromatin modification enzymes regulate gene expression by altering the accessibility of promoters to transcription factors. Several of these enzymes are dysregulated in rheumatoid arthritis,…
Abstract Number: 2224 • 2012 ACR/ARHP Annual Meeting
Oral Contraceptive Pill Use in Women with Ankylosing Spondylitis Is Associated with a Younger Age At Diagnosis
Dharini Mahendira¹, Arane Thavaneswaran², Adele Carty³, Nigil Haroon⁴, Ammepa Anton⁵, Laura A. Passalent⁶, Khalid A. Alnaqbi³, Laurie M. Savage⁷, Elin Aslanyan⁷ and Robert D. Inman⁸, ¹Rheumatology, St Michael's Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada, ⁶Allied Health, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Spondylitis Association of America, Van Nuys, CA, ⁸Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: While AS is traditionally recognized as a predominantly male disease, the impact of gender differences on AS pathogenesis has not been clearly established. Specifically,…
Abstract Number: 2225 • 2012 ACR/ARHP Annual Meeting
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Dominique L. Baeten¹, Stephan Bek², Jiawei Wei³, Arndt Brachat⁴, Joachim Sieper⁵, Paul Emery⁶, Jürgen Braun⁷, Desiree M. van der Heijde⁸, Iain B. McInnes⁹, Jacob M. van Laar¹⁰, R. Landewe¹¹, Paul Wordsworth¹², Jurgen Wollenhaupt¹³, Herbert Kellner¹⁴, Jacqueline E. Paramarta¹⁵, Arthur Bertolino¹⁶, Andrew Wright¹⁷ and Hueber Wolfgang², ¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Integrated Information Sciences (IIS), Beijing Novartis Pharma Co. Ltd., Shanghai,, China, ⁴Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, ⁵Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹⁰Newcastle University, Musculoskeletal Research Group, Newcastle, United Kingdom, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Nuffield Orthopaedic Centre, Oxford, United Kingdom, ¹³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ¹⁵Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹⁶Translational Medicine- 3rd Floor, Novartis Institutes for BioMedical Research, Basel, Switzerland, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has shown to be well tolerated and effective in active ankylosing spondylitis (AS) patients in a proof-of-concept trial1. Briefly, at Week (Wk) 6,…
Abstract Number: 2226 • 2012 ACR/ARHP Annual Meeting
Application of Classification Criteria for Psoriatic Arthritis to Patients of the Rotterdam Early Arthritis Cohort
Jos Van der Kaap¹, Johanna M.W. Hazes², M. Vis³, Ilya Tchetverikov⁴ and Jolanda J. Luime², ¹Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, VU University medical center, Amsterdam, Netherlands, ⁴Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) poses a diagnostic challenge due to lack of a clear case definition. This has led to varying reports on prevalence, which…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 2228 • 2012 ACR/ARHP Annual Meeting
The Caspar Classification Criteria and Response to TNF Blockade in Rheumatologists Practice: A Large Observational Cohort Study
Burkhard Moller¹, Almut Scherer², J. Dudler³, Bettina Weiss⁴, Nikhil Yawalkar⁵ and Peter M. Villiger⁶, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁴Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁵Dermatology, MD, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
The CASPAR classification criteria and response to TNF blockade in Rheumatologists' practice: A large observational cohort study Burkhard Möller, Almut Scherer, Jean Dudler, Bettina Weiss,…
Abstract Number: 2229 • 2012 ACR/ARHP Annual Meeting
Analysis of Clinical, CRP- and MRI- Responses to TNF-Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration
Anja Weiss¹, In-Ho Song², Hildrun Haibel², Joachim Listing³ and Joachim Sieper⁴, ¹German Rheumatism Research Centre, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: To investigate the impact of disease duration on treatment response in patients with axial spondylarthritis (SPA) treated with etanercept (ETA) or adalimumab (ADA). Methods:…
Abstract Number: 2230 • 2012 ACR/ARHP Annual Meeting
The Early Clinical Response of TNF-Alpha Blockers Is a Predictor of Metrology Outcome in Ankylosing Spondylitis
Eon Jeong Nam¹, Jung Soo Eun¹, Na Ri Kim¹, Jong Wan Kang¹, Churl Hyun Im¹ and Young Mo Kang², ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: TNF-a blocker is the only treatment that shows a significant effect on spinal inflammation and life quality of patients with ankylosing spondylitis (AS). However,…
Abstract Number: 2231 • 2012 ACR/ARHP Annual Meeting
Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: 2 Year Results of a Prospective Cohort Study
Leonard C. Harty¹, Alex Franciosi², Naomi Pettysan², Paul Rushe² and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Treatment resistant psoriatic arthritis (PsA) may render a patient unwell, disabled and incapable of work with previous reports suggesting that unemployment levels among PsA…
Abstract Number: 2232 • 2012 ACR/ARHP Annual Meeting
Performance of Berlin Criteria in Patients with EARLY Spondyloarthritis
Beatriz E. Joven¹, Milena Gobbo², Miguel A. Descalzo³, Eugenio De Miguel⁴ and Esperanza Group⁵, ¹Rheumatology, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, Spain, ²Research Unit, Spanish Society of Rheumatology., Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Madrid
Background/Purpose: Berlin criteria are a diagnostic algorithm based on calculation of the likelihood ratio (LR) product of currently available diagnostic test for spondyloarthritis (SpA). However,…
Abstract Number: 2233 • 2012 ACR/ARHP Annual Meeting
Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients
Lin Xie¹, Onur Baser², Ahong Huang³, Lu Li³, Elyse K. Fritschel³ and Li Wang⁴, ¹Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ²President/Adjunct Professor of Internal Medicine, STATinMED Research/The University of Michigan, Ann Arbor, MI, ³STATinMED Research, Dallas, TX, ⁴Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: To examine the economic burden, demographic and clinical characteristics of ankylosing spondylitis (AS) in the U.S. veteran population. Methods: A retrospective database analysis…
Abstract Number: 2234 • 2012 ACR/ARHP Annual Meeting
US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Frank Zhang¹, Stan Li² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Pricing and Market Access, Celgene Corporation, Warren, NJ, ³Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Etanercept (ETN) and Adalimumab (ADA) are commonly used biologic disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) patients (pts). However, little is known about…
Abstract Number: 2235 • 2012 ACR/ARHP Annual Meeting
How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters
Xenofon Baraliakos¹, Claudia Fritz², Joachim Listing³, Hildrun Haibel⁴, Joachim Sieper⁵ and Jürgen Braun⁶, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁵Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].